T A B L E O F C O N T E N

Main results
We identified seven studies (total number of participants = 189), including one randomised controlled trial (RCT), which assessed the adrenal function. None of the studies assessed the HPA axis at the level of the hypothalamus, pituitary, or both. Due to substantial differences between studies, results could not be pooled. All studies had some methodological limitations. The included studies demonstrated that adrenal insufficiency occurs in nearly all patients in the first days after cessation of glucocorticoid treatment for childhood ALL. The majority of patients recovered within a few weeks, but a small amount of patients had ongoing adrenal insufficiency lasting up to 34 weeks. In the RCT, the occurrence and duration of adrenal insufficiency did not differ between the prednisolone and dexamethasone arms. In one study included in the review it appeared that treatment with fluconazole prolonged the duration of adrenal insufficiency.
Authors' conclusions
Based on the available evidence, we conclude that adrenal insufficiency commonly occurs in the first days after cessation of glucocorticoid therapy for childhood ALL, but the exact duration is unclear. Since no data on the level of the hypothalamus and the pituitary were available we cannot make any conclusions regarding those outcomes. Clinicians should consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL, to reduce the risk of life-threatening complications. However, more high-quality research is needed for evidence-based guidelines for glucocorticoid replacement therapy.
Special attention should be paid to patients receiving fluconazole therapy, and perhaps similar antifungal drugs, as this may prolong the duration of adrenal insufficiency.
P L A I N L A N G U A G E S U M M A R Y
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia (ALL) is the most frequent type of cancer in children. Glucocorticoids, like prednisone and dexamethasone, play a major role in the treatment of ALL. However, high-dose glucocorticoids may cause HPA axis suppression. Suppression of the HPA axis, resulting in inadequate cortisol production, may cause an impaired response to stressors (e.g. trauma, surgery or inflammation) and an inadequate host defence against infections and remains a cause of morbidity and death in childhood. The occurrence and duration of HPA axis suppression after glucocorticoid therapy for childhood ALL are unclear.
This systematic review included six cohort studies and one randomised study, which assessed the adrenal function. None of the studies assessed the HPA axis at the level of the hypothalamus, pituitary, or both. All studies had some methodological limitations and results could not be pooled because of the heterogeneity. Adrenal insufficiency occurred in nearly all of the patients in the first days after cessation of glucocorticoid therapy. The majority of patients recovered within a few weeks, but a small number of patients had ongoing adrenal insufficiency lasting up to 34 weeks. More high-quality research is needed to assess the exact occurrence and duration of HPA axis suppression in order to formulate adequate guidelines for glucocorticoid replacement therapy.
B A C K G R O U N D
Of all malignancies in children, acute lymphoblastic leukaemia (ALL) is the most frequent type. Annually, approximately 120 children with ALL are newly diagnosed in the Netherlands (DCOG 2008) . Since treatment and survival rates of childhood ALL have substantially improved over time, morbidity and mortality due to treatment-related side effects become increasingly important.
Unfortunately, up to 5% of children die because of the toxic side effects of treatment, and this percentage becomes even greater in higher-risk subgroups. Our aim was to undertake a systematic review of the HPA axis function after glucocorticoid therapy for childhood ALL. On this basis, adequate guidelines for glucocorticoid substitution can be formulated and implemented to reduce the risk of infection in childhood ALL.
O B J E C T I V E S Primary objective
• To examine the occurrence of HPA axis suppression after (each cycle of ) glucocorticoid therapy for childhood ALL.
• To examine the duration of HPA axis suppression after treatment with glucocorticoids for childhood ALL.
Secondary objectives
To examine whether the HPA axis function after administration of glucocorticoids is dependent on:
• the moment of testing after cessation of glucocorticoid therapy
• the (cumulative) dose of glucocorticoids • the type of glucocorticoids; prednisone, prednisolone or dexamethasone
• the duration of glucocorticoid therapy • the method of cessation of glucocorticoid therapy; abrupt or gradual
M E T H O D S
Criteria for considering studies for this review
Types of studies
All study designs, except case reports and patient series with fewer than 10 patients, examining the effect of glucocorticoid therapy for childhood ALL on HPA axis function. This effect can be evaluated both during treatment for ALL (after cessation of a glucocorticoid course) and after the end of all ALL treatment. Discrepancies concerning the definition of a cohort study between review authors were resolved by consensus. No third party arbitration was needed.
Types of participants
Patients who were treated with glucocorticoids for ALL between the age of 0 and 18 years, irrespective of the duration of followup after the end of glucocorticoid therapy. Exclusion criteria are cranial radiotherapy, since this may damage the HPA axis, and testing HPA axis function by a CRH stimulation test only, since this test is only indicated in patients with a central disorder of the HPA axis (Maghnie 2005; Van Tijn 2008).
Types of interventions
Glucocorticoid therapy (prednisone, prednisolone, dexamethasone) during treatment for ALL. The intervention was not compared to a control group, since this was not available (with the exception of the included randomised controlled trials (RCT)).
Types of outcome measures
HPA axis function, measured by early morning plasma cortisol levels (between 8 and 10 a.m.) or by stimulation tests (e.g. (lowdose) ACTH stimulation test or glucagon stimulation test). We used the cut-off limit as defined by the authors of the original studies.
Search methods for identification of studies
See: Cochrane Childhood Cancer Group methods used in reviews (Module CCG). The objective of the literature search was to identify all studies, except case reports and case series, reporting on HPA axis function after glucocorticoid therapy for childhood ALL.
Electronic searches
We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (in The Cochrane Library, issue 3, 2010), MEDLINE/PubMed (from 1945 to July 2010) and EMBASE/Ovid (from 1980 to July 2010). The search strategies for the different electronic databases (using a combination of controlled vocabulary and text words) are shown in the appendices (Appendix 1, Appendix 2, Appendix 3).
Searching other resources
We located information about trials not registered in CENTRAL, MEDLINE or EMBASE, either published or unpublished, by searching the reference lists of relevant articles and review articles. We also scanned the International Standard Randomized Controlled Trial Number (ISRCTN) register and the National Institutes of Health (NIH) register for ongoing trials: http:// www.controlled-trials.com (both screened July 2010; for the search strategy see Appendix 5). We imposed no language restrictions. We will update the searches every 2 years.
Data collection and analysis
Selection of studies
After performing the search strategy, two review authors independently selected studies meeting the inclusion criteria. Discrepancies between review authors were resolved by consensus. No third party arbitration was needed. We obtained in full any study that seemed to meet the inclusion criteria on grounds of the title or abstract or both, for closer inspection. We clearly stated reasons for exclusion of any study considered for this review.
Data extraction and management
Data extraction was performed by one review author using standardised forms and checked by another review author. The review authors were not blinded to the journal, the authors or the institution. We extracted data on the following categories: study characteristics, participants, interventions, outcome measures, length of follow-up, risk factors, and 'Risk of bias' assessment. Discrepancies between authors were resolved by consensus. No third party arbitration was needed.
Assessment of risk of bias in included studies
The assessment of risk of bias was based on previously described checklists for observational studies according to Evidence-Based Medicine Criteria (Grimes 2002; Laupacis 1994). The assessment of risk of bias of the included studies was performed by one review author and checked by another review author. The 'Risk of bias' assessment criteria for observational studies are described in Table  1 . For RCTs we used the 'Risk of bias' items as described in the module of the Childhood Cancer Group, which are based on the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2009; Module CCG) (see Table 2 ). Discrepancies between review authors were resolved by consensus. No third party arbitration was needed.
Measures of treatment effect
Prevalence of HPA axis suppression at several follow-up time points and time duration of HPA axis suppression.
Dealing with missing data
We contacted authors of individual studies for clarification of unclear data or to obtain missing data regarding selection of studies, the 'Risk of bias' assessment and data extraction.
Assessment of heterogeneity
We planned to assess heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity, that is the I 2 statistic. However, since we were not able to pool the results of the included studies, this was not applicable.
Assessment of reporting biases
We planned to use a funnel plot to quantify the potential presence of publication bias. However, since we were not able to pool the results of the included studies, this was not applicable.
Data synthesis
We planned to perform analyses using the statistical software Comprehensive Meta Analysis (Biostat, Inc, USA). Across the various studies, we planned to conduct a multivariate linear meta-regression analysis model with a backwards selection strategy (P < 0.10) to examine the relation between potential predictive factors and HPA axis suppression. However, since we were not able to pool the results of the included studies, this was not applicable and we described the results of the individual studies separately. Kaplan-Meier curves were calculated using SPSS version 15.0.
Sensitivity analysis
We planned to perform a sensitivity analysis for the used 'Risk of bias' assessment criteria. However, since we were not able to pool the results of the included studies, this was not applicable. 
R E S U L T S Description of studies
Results of the search
Running the searches in the electronic databases of CENTRAL, MEDLINE/PubMed and EMBASE/Ovid revealed a total of 1388 references. Initial screening of the titles and abstracts excluded 1375 references that clearly did not fulfil all criteria for considering studies for this review. Of the remaining 13 references we examined the full-text articles. Seven of the 13 full-text articles were eligible for inclusion in this systematic review, whereas the other six were not. The reasons for exclusion are illustrated in Characteristics of excluded studies. Scanning the reference list of relevant articles and reviews did not identify any additional eligible studies. Scanning the conference proceedings of SIOP and ASCO did not identify any eligible studies and scanning the ongoing trials databases did not identify any ongoing studies. In summary, seven articles could be included in this review. We made attempts to contact authors to clarify aspects of the study design and data analysis. Characteristics of the included studies are summarised in the Characteristics of included studies table.
Included studies
All included studies evaluated adrenal function after glucocorticoid therapy for childhood ALL. None of the studies assessed the HPA axis at the level of the hypothalamus, pituitary or both. The total number of patients included in the studies was 189. The seven included studies examined the adrenal function after different types, doses and durations of glucocorticoid therapy and after different methods of cessation of glucocorticoid therapy. Three studies examined the effect of dexamethasone on adrenal function 
Excluded studies
Information on the six studies excluded during examination of the full-text articles is included in the Characteristics of excluded studies table. The most common reasons for exclusion were cranial irradiation therapy or the lack of (adequate) HPA axis function tests.
Risk of bias in included studies
Cohort studies For the evaluation of the 'internal validity' of the six included cohort studies we assessed the risk of selection bias, attrition bias, detection bias and confounding that was present in the included studies. Based on additional information provided by the authors, there was a low risk of selection bias (based on the representativeness of the study group) in four of the six studies as the study group consisted of more than 90% of the original cohort ( Table 3 .
Randomised controlled trial
For the included RCT we evaluated the risk of selection bias, performance bias, detection bias, attrition bias, reporting bias and other biases. Based on additional information provided by the authors, no selection bias (based on sequence generation and concealment of allocation) was present (Einaudi 2008). Performance bias (based on the blinding of care providers and participants) and detection bias (based on the blinding of the outcome assessors) could not be ruled out (Einaudi 2008). The RCT was susceptible for reporting bias as not all of the study's pre-specified primary outcomes were reported (Einaudi 2008). The risk on attrition bias (based on the completeness of outcome data) or other bias (i.e. based on potential source of bias related to the specific study design, premature termination of the study due to some data-dependent process, extreme baseline imbalance) in the RCT was low (Einaudi 2008). See also Table 4 .
Effects of interventions
Adrenal insufficiency (occurrence and duration) Data on the prevalence and the duration of adrenal insufficiency after treatment with glucocorticoid therapy for childhood ALL could be extracted from all included studies. However, it should be noted that the individual studies used different types and (cumulative) doses of glucocorticoids. In addition, differences in duration and method of cessation of glucocorticoid therapy occurred. Methods of testing adrenal function varied as well. Due to this heterogeneity pooling of results was not possible. For more information see Characteristics of included studies. Two studies used the ACTH stimulation test with comparable cut-off limits (stimulated cortisol: 18 µg/dL (500 nmol/L)) for measuring adrenal function (Felner 2000; Petersen 2003). Before glucocorticoid therapy, adrenal function was normal in all patients in the study of Felner 2000. However, all 10 patients (100%) had insufficient cortisol levels 1 day after abrupt cessation of 28 days of dexamethasone at 6 mg/m 2 /day. Three out of 10 patients (30%) had ongoing adrenal insufficiency after 4 weeks but all recovered after 8 weeks. In the study of Petersen 2003, two types of glucocorticoid therapy were assessed; induction therapy comprising 35 days of prednisolone 60 mg/m 2 /day with tapering over 9 days and re-induction therapy comprising 21 days of dexamethasone 10 mg/m 2 /day with tapering over 9 days. Re-induction therapy succeeded induction therapy, thus patients in the dexamethasone group also received induction therapy with prednisolone. HPA axis function was not assessed before glucocorticoid therapy. Af-ter induction therapy (n = 10), seven out of 10 patients (70%) had adrenal insufficiency within the first week. Six patients (60%) had ongoing adrenal insufficiency after 3 weeks and four patients (40%) after 7 weeks. These four patients remained insufficient at the end of their follow-up, that is after 10, 11, 11 and 19 weeks, respectively. The latter patient, with no recovery by 19 weeks, received, in addition to the induction therapy, two 1-week long reinduction courses including prednisolone 60 mg/m 2 /day during adrenal insufficiency. After re-induction therapy (n = 7), five out of seven patients (71%) had adrenal insufficiency within the first week. Four patients (57%) had ongoing adrenal insufficiency after 3 weeks and three patients (43%) after 7 weeks. These three patients remained insufficient at the end of their follow-up, that is after 16, 33 and 34 weeks, respectively. One of these patients, with no recovery after 16 weeks, received an additional 1-week long reinduction course of prednisolone 60 mg/m 2 /day during the period of adrenal insufficiency. The other two patients, with no recovery after 33 and 34 weeks, received three additional 1-week long reinduction courses including prednisolone 60 mg/m 2 /day during adrenal insufficiency. See Table 5 for an overview and Figure 1 for the Kaplan-Meier curve of the prevalence and duration of adrenal insufficiency in the studies that used an ACTH suppression test. /day. Four weeks after its completion this was followed by maintenance therapy every 4 weeks consisting of 7 days of dexamethasone 8 mg/m 2 /day. Baseline cortisol levels before induction therapy and 2 weeks afterwards were not significantly different between the adrenal suppressed and the unsuppressed group. Eleven out of 24 patients (46%) had adrenal insufficiency 2 weeks after abrupt cessation of 28 days of induction therapy. Nine patients (38%) had ongoing adrenal insufficiency after 4 weeks, seven patients (29%) after 8 weeks and three patients (13%) after 12 weeks. The latter three patients remained insufficient at the end of followup at 20 weeks. In the study of Rix 2005, three types of glucocorticoid treatment were evaluated. All patients (standard risk, intermediate risk and high risk) received induction therapy (22 patients in total were tested afterwards; for two patients no information was available) comprising 35 days of prednisolone 60 mg/m 2 /day with tapering over 9 days. All patients also received 7-day courses of prednisolone 60 mg/m 2 /day without tapering (13 patients in total were tested afterwards) and intermediate-risk and high-risk patients received additionally 21 days of dexamethasone 10 mg/m 2 /day with tapering over 9 days (7 patients in total were tested afterwards). The 7-day course of prednisolone and the dexamethasone course followed induction therapy. The intermediate-risk group received the dexamethasone course before the 7-day course of prednisolone and the high-risk group received the dexamethasone course after the 7-day course of prednisolone. Based on additional information provided by the authors, 13 patients were tested before induction therapy, and all had a normal adrenal function. Sixteen patients out of 22 (73%) had adrenal insufficiency 1 day after cessation of induction therapy; one of them was lost to follow-up thereafter. Five out of 22 patients (23%) were not tested at this time point. Eight patients (36%) had ongoing adrenal insufficiency after 3 days; two of them were lost to follow-up afterwards. Seven patients (32%) (including the patient that was lost to follow-up) with no confirmed adrenal recovery were not tested at this time point. Eight patients (36%) had ongoing adrenal insufficiency at the end of follow-up of 5 days. Three patients (14%) (i.e., the three patients that were lost to follow-up) with no confirmed adrenal recovery were not tested at this time point. After 7-day courses of prednisolone, all 13 patients (100%) remained insufficient at the end of the follow-up period of 2 days. However, two patients out of 13 (15%) already had an insufficient adrenal function before prednisolone therapy. Five patients out of seven (71%) underwent a low-dose ACTH test before dexamethasone therapy; all patients had sufficient cortisol levels. One day after the dexamethasone course, two out of seven patients (29%) had adrenal insufficiency; one of them was lost to follow-up thereafter. Five out of seven patients (71%) were not tested at this time point. Three patients (43%) had ongoing adrenal insufficiency after 3 days; one of them was lost to follow-up afterwards. Two patients (29%) (including the patient that was lost to follow-up) with no confirmed adrenal recovery were not tested at this time point. One patient (14%) had ongoing adrenal insufficiency at the end of the follow-up period of 7 days. Two patients (29%) (i.e., the two patients that were lost to follow-up) with no confirmed adrenal recovery were not tested at this time point. In the study of Einaudi 2008, two randomised arms of glucocorticoid therapy were examined; 22 days of prednisolone 60 mg/ m 2 /day with tapering over 9 days (n = 40) and 22 days of dexamethasone 10 mg/m 2 /day with tapering over 9 days (n = 24). Both groups of patients received 7 days of prednisolone 60 mg/m 2 /day in advance. At diagnosis, basal cortisol values were within the normal range in all patients. In the prednisolone arm, 32 out of 40 patients (80%) had adrenal insufficiency 1 day after cessation of glucocorticoid therapy, eight patients (20%) had ongoing adrenal insufficiency after 7 to 14 days (in the Kaplan Meier curve marked as 14 days) and five patients (13%) after 28 days. All patients (100%) recovered in 10 weeks (in the Kaplan Meier curve marked as 10 weeks). In the dexamethasone arm, 20 out of 24 patients (83%) had adrenal insufficiency 1 day after cessation of glucocorticoid therapy. Four patients (17%) had ongoing adrenal insufficiency after 7 to 14 days (in the Kaplan Meier curve marked as 14 days) and three patients (13%) after 28 days. All patients (100%) recovered in 10 weeks (in the Kaplan Meier curve marked as 10 weeks). See Table 6 for an overview and Figure 2 for the Kaplan-Meier curve of the prevalence and duration of adrenal insufficiency in the studies that used a low-dose ACTH test. Two studies used basal morning cortisol values for measuring adrenal function. In the study of Cunha 2004, including 35 children, median basal cortisol levels were inhibited on the 8th day (1.2 µg/dL, range 0.9 to 132.7 µg/dL) and the 28th day (0.9 µg/ dL, range 0.9 to 6.6 µg/dL) of 28 days of dexamethasone 6 mg/m 2 / day and 48 hours after cessation (over 10 days) of dexamethasone treatment (2.4 µg/dL, range 0.9 to 11.2 µg/dL) compared to preglucocorticoid therapy levels (17.5 µg/dL, range 7.6 to 40.9 µg/ dL) (P = 0.01 for the three tests versus pre-glucocorticoid levels). Median basal cortisol levels 1 month after cessation of dexamethasone treatment (12.4 µg/dL, range 1.8 to 29.0 µg/dL), although slightly lower, did not show a significant difference compared with pre-glucocorticoid therapy levels. No data on patient level were available. In the study of Kuperman 2001, including 15 children, mean basal cortisol levels (± standard error of the mean) were significantly (P < 0.05) lower on day 7 (10.8 ± 1.0 µg/dL) and day 14 (11.5 ± 2.0 µg/dL) after abrupt cessation of 42 days of dexamethasone 6 mg/ m 2 /day than pretreatment (17.8 ± 1.3 µg/dL). Levels at day 7 and day 14 did not differ significantly. Based on additional information provided by the authors, all patients (100%) had sufficient basal cortisol levels at diagnosis (> 7 µg/dL), whereas four out of 15 (27%) patients had insufficient basal cortisol levels 7 days after cessation of dexamethasone therapy. One patient was lost to follow-up thereafter. Fourteen days after cessation of dexamethasone therapy, four (29%) out of 14 patients had insufficient basal cortisol levels. It should be noted that one of them had a sufficient basal cortisol level 7 days earlier. Therefore, these data could not be presented in a Kaplan-Meier curve. See Table 7 for an overview of the prevalence and duration of adrenal insufficiency in the studies that used basal morning cortisol values.
Other outcome measures
Identifying whether the adrenal function after administration of glucocorticoids was dependent on the moment of testing, the (cumulative) dose, type or duration of glucocorticoid therapy or the method of cessation of glucocorticoid therapy was not possible due to the heterogeneity.
D I S C U S S I O N
With the improvement of survival of childhood ALL, treatmentrelated side effects become increasingly relevant. Glucocorticoids play an important role in the treatment of childhood ALL, but supraphysiological doses may suppress the HPA axis, resulting in an impaired stress response and an inadequate defence against infections (Henzen 2000; Krasner 1999). Patients with HPA axis suppression may benefit from glucocorticoid replacement therapy (e.g. hydrocortisone) to reduce the risk of life-threatening complications. Unfortunately, little information is known on the occurrence and duration of HPA axis suppression and adequate guidelines for glucocorticoid substitution are lacking. This is the first systematic review evaluating HPA axis function after treatment with glucocorticoid therapy for childhood ALL.
We identified seven studies evaluating adrenal function after treatment with glucocorticoid therapy for childhood ALL, including one RCT. None of the studies evaluated the HPA axis at the level of the hypothalamus, pituitary, or both. Due to the substantial differences in types and (cumulative) doses of glucocorticoids used, in duration and method of cessation of glucocorticoid therapy and in method of testing adrenal function, pooling of results was not possible. The included studies demonstrated that adrenal insufficiency occurs in nearly all patients in the first days after cessation of glucocorticoid treatment for childhood ALL. The majority of patients recovered from adrenal insufficiency within 7 weeks. However, a small amount of patients had ongoing adrenal insufficiency lasting up to 34 weeks. At first impression, no significant differences in the occurrence and duration of adrenal insufficiency between different types, (cumulative) doses, durations and methods of cessation of glucocorticoid therapy were present, but due to the heterogeneity between studies we were not able to assess this further. Due to this, and the small patient numbers in the included studies (i.e. low power), definitive conclusions cannot thus not be provided. Only one study was designed as an RCT, enabling comparison between two different types of glucocorticoid therapy; prednisolone versus dexamethasone (Einaudi 2008). Both treatment groups received prednisolone prior to the randomised treatment. The occurrence and duration of adrenal insufficiency did not differ between the treatment arms.
Previous studies demonstrated adrenal suppression after high-dose fluconazole therapy (Albert 2001; Shibata 2001). Only one of the studies that was included in this review, reported on fluconazole therapy (Petersen 2003). In this study, two of the three patients receiving fluconazole had ongoing adrenal insufficiency 8 months after cessation of dexamethasone therapy, whereas the third patient recovered after 3 weeks. It should be taken into account that fluconazole therapy may have influenced the duration of adrenal insufficiency in these patients.
Due to the paucity of RCTs on HPA axis suppression after glucocorticoid therapy in childhood ALL, the majority of studies included in this systematic review were uncontrolled studies. Only one RCT was identified. Due to the lack of control groups it was impossible to evaluate possible causes of HPA axis suppression other than glucocorticoid therapy. Furthermore, all included studies used biochemical markers to evaluate adrenal insufficiency; they did not discuss the clinical consequences of adrenal insufficiency. All included studies had methodological limitations, but currently, this is the best available evidence on this topic.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Based on the currently available evidence, we can conclude that adrenal insufficiency in the first days after cessation of glucocorticoid therapy for childhood ALL routinely occurs, but the exact duration of adrenal insufficiency remains unclear. Since no data on the level of the hypothalamus and the pituitary were available we cannot make any conclusions regarding those outcomes. The majority of patients seem to recover within 3 days to 7 weeks. However, a small number of patients have prolonged adrenal insufficiency, persisting up to several months. Clinicians should consider prescribing glucocorticoid replacement therapy (e.g. hydrocortisone) during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL, to reduce the risk of life-threatening complications. If replacement therapy is indicated, the beneficial effects and side effects should be evaluated. Until results of adequate future studies on the incidence and duration of HPA axis suppression are available, an HPA axis stimulation test can be recommended , for example, 2 months after cessation of glucocorticoids, to determine if the HPA axis has recovered and if replacement therapy during periods of stress can be discontinued. Exclusively morning cortisol levels are inappropriate to evaluate HPA axis recovery because they only reflect basal cortisol prediction and not the ability of the HPA axis to respond to stress (Agwu 1999).
No definitive conclusions regarding differences in the occurrence and duration of adrenal insufficiency between the type (predniso(lo)ne versus dexamethasone), (cumulative) dose, duration and method of cessation (abrupt or gradual) of glucocorticoid therapy can be made.
Implications for research
Studies examining HPA axis suppression after high-dose glucocorticoid therapy for childhood ALL are scarce, especially RCTs. High-quality research regarding the occurrence and duration of HPA axis suppression after glucocorticoid therapy for childhood ALL is needed in order to formulate adequate evidence-based guidelines for glucocorticoid replacement therapy. It will also be of interest to compare the serious adverse effects in patients with, and without, persistent HPA axis suppression. In addition, there is a need for studies evaluating the long-term effects of glucocorticoid therapy on the HPA axis.
Future studies should focus on identifying differences in the effect of type, (cumulative) dose, repeated exposure, duration and method of cessation of glucocorticoid therapy on the occurrence and duration of HPA axis suppression. The number of included patients should be sufficient to obtain the power needed for reliable results.
Furthermore, an interesting and relevant topic for future research would be the (genetic) susceptibility of individuals for HPA axis suppression after glucocorticoid treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Cunha 2004
Methods
Study Notes 0 patients were lost to follow-up Length of follow-up after glucocorticoid therapy: patients with suppressed levels underwent further low-dose ACTH tests between 7 and 14 days from the last glucocorticoid dose and every 2 weeks thereafter until cortisol levels normalised. The total follow-up duration was 10 weeks Risk factors were not evaluated Duration of glucocorticoid therapy: induction therapy: 35 days of prednisolone + 9 days' tapering doses. 1 patient received an additional 14 days of prednisolone. Re-induction therapy: 21 days of dexamethasone + 9 days' tapering doses. The high-risk patients received 14 days of prednisolone 4 and 8 weeks prior to dexamethasone therapy. After the dexamethasone course, the high-risk patients also received prednisolone for 1 week (n = 1) or 3 weeks (n = 2) Methods of cessation of glucocorticoid therapy: 50% each 3 days, over 9 days in total No control intervention 
D A T A A N D A N A L Y S E S
This review has no analyses. • if it consisted of more than 90% of the original cohort of ALL patients treated with glucocorticoids
A D D I T I O N A L T A B L E S
• or if it was a random sample with respect to the treatment Reporting bias (well defined: yes/no):
• if the treatment protocol was mentioned • and if the (cumulative) dose of glucocorticoid treatment was mentioned
• and if the type of glucocorticoid treatment was mentioned
• and if the duration of glucocorticoid treatment was mentioned
• and if the method of cessation of glucocorticoid treatment was mentioned
Follow-up
Attrition bias (adequate: yes/no):
• if the outcome was assessed at the end date of the study for 60% to 90% of the study group
• or if the outcome was assessed for more than 90% of the study group but with an unknown end date Reporting bias (well-defined: yes/no):
• if the length of follow-up was mentioned • and if the frequency of measuring the outcomes was mentioned
Outcome
Detection bias (blinding: yes/no):
• if the outcome assessor was blinded to glucocorticoid treatment Reporting bias (well-defined: yes/no):
• if the methods of detection were described • if the outcome definition was objective and precise Risk estimation Confounding (adjustment for other factors: yes/no):
• if important prognostic factors (i.e. age, sex, cotreatment) or follow-up were taken adequately into account Analysis (well-defined: yes/no):
• if a relative risk, odds ratio, attributable risk, linear or logistic regression model, mean difference, or Chi 2 statistic was calculated Table 2 . Risk of bias assessment criteria for randomised controlled trials Selection bias Sequence generation (adequate: yes/no):
• if the rule for allocating interventions to participants was based on some chance (random) process Allocation concealment (adequate: yes/no):
• if the randomisation method did not allow investigator and participant to know or influence the allocation of treatment before eligible participants entered the study / Performance bias Blinding of care providers (yes/no):
• if knowledge of the allocated intervention was adequately prevented during the study Blinding of participants (yes/no) • if knowledge of the allocated intervention was adequately prevented during the study
Detection bias
Blinding of outcome assessors (yes/no; assessed for each outcome separately):
• if knowledge of the allocated intervention was adequately prevented during the study
Attrition bias
Incomplete outcome data (adequate: yes/no; assessed for each outcome separately):
• if incomplete outcome (attrition and exclusions) data have been adequately addressed
Reporting bias
Selective outcome reporting (yes/no):
• if the reports of the study were free of suggestion of selective outcome reporting
Other bias
Other bias (yes/no):
• if the study was free of other problems (i.e. potential source of bias related to the specific study design, premature termination of the study due to some data-dependent process, extreme baseline imbalance) that could put it at a high risk of bias Time after cessation 1 week 3 weeks 7 weeks End of follow-up: 16, 33 and 34 weeks, respectively n insufficient/n total 5/7 4/7 3/7 2/7 a One patient received additional 840 mg/m 2 prednisolone during the period of adrenal insufficiency. b These patients received prednisolone 2257.5 mg/m 2 as induction therapy before. Three high-risk patients received additional 560 mg/m 2 prednisolone in advance. One patient received additional 420 mg/m 2 prednisolone during the period of adrenal insufficiency and two patients received additional 1260 mg/m 2 prednisolone during the period of adrenal insufficiency. a Four weeks after completion of the induction therapy, the patients received maintenance therapy consisting of a 7-day course of highdose dexamethasone 8 mg/m 2 /day, every 4 weeks. The cumulative dose depended on how long the patient had been followed up. b All patients first received prednisolone (cumulative dose 2257.5 mg/m 2 ). c After 7 days of prednisone (60 mg/m 2 /day, cumulative dose: 420 mg/m 2 ). 
A P P E N D I C E S Appendix 1. Search strategy for PubMed
